Solid Biosciences Inc. Finance Lease, Liability, to be Paid, Remainder of Fiscal Year
Solid Biosciences Inc. (SLDB) had Finance Lease, Liability, to be Paid, Remainder of Fiscal Year of $69.00 thousand as of 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Notes › Leases
us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear · last filed 2019-11-12
- 2019-09-30: Finance Lease, Liability, to be Paid, Remainder of Fiscal Year $69.00K.
- 2019-06-30: Finance Lease, Liability, to be Paid, Remainder of Fiscal Year $138.00K.
- 2019-03-31: Finance Lease, Liability, to be Paid, Remainder of Fiscal Year $206.00K.
- 2018-12-31: Finance Lease, Liability, to be Paid, Remainder of Fiscal Year $276.00K.
| Period end | Finance Lease, Liability, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2019-09-30 | $69.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $138.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $206.00K 10-Q · filed 2019-05-13 |
| 2018-12-31 | $276.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |